CTEV

Claritev Corporation (CTEV)
Healthcare • Health Information Services • $22.71 • MCap: 387,155,264 🌐
https://www.claritev.com • Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.
Buy Decision Core
Total Score
48
Business Quality
12
Financial Strength
11
Growth Outlook
1
Momentum
3
Price Action
Current
22.71
52W High
72.58
52W Low
13.47
Above 50DMA
28.14 (-19.29%)
Above 200DMA
31.42 (-27.73%)
Relative Strength
Relative Strength
-0.28
RS 3M
-0.07
RS 6M
-0.16
RS 9M
-0.68
RS 12M
-0.42
Fundamentals
Revenue Growth
0.06%
Earnings Growth
0%
ROE
0%
ROA
0.01%
Valuation
PE (Fwd)
3.32
PEG
0
P/B
-1.60
Upside
65.86%
Risk
Beta
0.70
Short %
0.10
Risk Score
9.00
Analyst
Rating
buy
Target
37.67
Beta
0.70
Analysts
0


Total Score
48
Upside
65.86%
Relative Strength
-0.28
Beta
0.70
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Trading below book value
  • Analyst upside exceeds 15%
Key Risks
  • Weak long-term relative strength
Score Breakdown
Business
12
Financial
11
Growth
1
Valuation
15
Risk
3
Momentum
3
Technical
52W High: 72.58
52W Low: 13.47
Above 50DMA: -19.29%
Above 200DMA: -27.73%
Valuation
Forward PE: 3.32
PEG: 0
P/B: -1.60
Upside: 65.86%
Risk
Beta: 0.70
Short Float: 0.10%
ROE: 0%
ROA: 0.01%